Capricor Therapeutics, Inc. (CAPR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Capricor Therapeutics (CAPR) Q1 2026: $36.8M Operating Expense Signals Full-Scale Launch Readiness Amid NS Pharma Standoff
  May 13, 2026
• Capricor Therapeutics (CAPR) Q4 2025: HOPE III Data Drives 91% Cardiomyopathy Progression Slowdown, Readying for Transformational Launch
  March 13, 2026
• Capricor Therapeutics (CAPR) Q3 2025: R&D Spend Rises 65% as HOPE III Phase III Data Nears Pivotal FDA Decision
  November 11, 2025
• Capricorn Therapeutics (CAPR) Q2 2025: R&D Spend Up 72% as FDA Path for Daromyosil Remains Unclear
  August 13, 2025
• Capricorn Therapeutics (CAPR) Q1 2025: R&D Spend Jumps 60% as BLA Approval Path Intensifies
  July 06, 2025
• Capricor (CAPR) Q3 2024: $1.5B Milestone Path as Daromyosel BLA Filing Targets 8,000-Patient Cardiac Market
  November 13, 2024
• Capricor Therapeutics (CAPR) Q2 2024: $700M Milestone Path Anchored by BLA Acceleration and Cardiac Label Expansion
  August 07, 2024
• Capricor Therapeutics (CAPR) Q1 2024: $10M Milestone Payment Accelerates BLA Path for CAP-1002
  May 13, 2024
• Capricor Therapeutics (CAPR) Q4 2023: $10M Milestone Payment Signals Accelerated BLA Path for CAP-1002
  February 29, 2024

Browse all companies